Pathologic regulation of collagen I by an aberrant protein phosphatase 2A/histone deacetylase C4/MicroRNA-29 signal axis in idiopathic pulmonary fibrosis fibroblasts

American Journal of Respiratory Cell and Molecular Biology

Volumn 53, Issue 3, 2015, Pages 391-399

  Khalil, Wajahat ^a   Xia, Hong ^a   Bodempudi, Vidya ^a   Kahm, Judy ^a   Hergert, Polla ^a   Smith, Karen ^a   Peterson, Mark ^a   Parker, Matthew ^a   Herrera, Jeremy ^a   Bitterman, Peter B ^a   Henke, Craig A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

HDAC4; IPF fibroblasts; miR 29; PP2A; Type I collagen

Indexed keywords

ADENOVIRUS VECTOR; COLLAGEN TYPE 1; HISTONE DEACETYLASE 4; LENTIVIRUS VECTOR; MICRORNA 29; MICRORNA 29C; PHOSPHOPROTEIN PHOSPHATASE 2A; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; HDAC4 PROTEIN, HUMAN; HISTONE DEACETYLASE; MICRORNA; MIRN29 MICRORNA, HUMAN; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN PHOSPHATASE 2C; REPRESSOR PROTEIN;

ADULT; ARTICLE; CELL INTERACTION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSING ALVEOLITIS; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LIMIT OF QUANTITATION; NONHUMAN; PHENOTYPE; PRIMARY CELL LINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RESEARCH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; CELL CULTURE; CELL NUCLEUS; ENZYMOLOGY; GENETIC EPIGENESIS; METABOLISM; PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TRANSPORT;

CELL NUCLEUS; CELLS, CULTURED; COLLAGEN TYPE I; EPIGENESIS, GENETIC; FIBROBLASTS; HISTONE DEACETYLASES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MICRORNAS; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION;

EID: 84941552494     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2014-0150OC     Document Type: Article

References (48)

1. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994;150:967-972.
2. Mannino DM, Etzel RA, Parrish RG. Pulmonary fibrosis deaths in the United States, 1979-1991: an analysis of multiple-cause mortality data. Am J Respir Crit Care Med 1996;153:1548-1552.
3. Noble PW. Idiopathic pulmonary fibrosis: natural history and prognosis. Clin Chest Med 2006;27(1 Suppl 1):S11-S16.
4. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810-816.
5. King TE, Costabel U, Cordier JF, DoPico GA, DuBois RM, Lynch D, Lynch JP III, Myers J, Panos R, Raghu G, et al. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment: International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-664.
6. Basset F, Ferrans VJ, Soler P, Takemura T, Fukuda Y, Crystal RG. Intraluminal fibrosis in interstitial lung disorders. Am J Pathol 1986;122:443-461.
7. Fukuda Y, Ishizaki M, Masuda Y, Kimura G, Kawanami O, Masugi Y. The role of intraalveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage. Am J Pathol 1987;126:171-182.
8. Kuhn C III, Boldt J, King TE Jr, Crouch E, Vartio T, McDonald JA. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis 1989;140:1693-1703.
9. Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis: ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol 1991;138:1257-1265.
10. Noble PW, Homer RJ. Idiopathic pulmonary fibrosis: new insights into pathogenesis. Clin Chest Med 2004;25:749-758.
11. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-151.
12. Cool CD, Groshong SD, Rai PR, Henson PM, Stewart JS, Brown KK. Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med 2006;174:654-658.
13. Sengupta S, Den Boon JA, Chen IH, Newton MA, Stanhope SA, Cheng YJ, Chen CJ, Hildesheim A, Sugden B, Ahlquist P. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA 2008;105:5874-5878.
14. Cushing L, Kuang PP, Qian J, Shao F, Wu J, Little F, Thannickal VJ, Cardosa WV, Lu J. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol 2011;45:287-294.
15. Pandit KV, Milosevic J, Kaminiski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res 2011;157:191-199.
16. Xia H, Diebold D, Nho R, Perlman D, Kleidon J, Kahm J, Avdulov S, Peterson M, Nerva J, Bitterman P, et al. Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis. J Exp Med 2008;205:1659-1672.
17. Xia H, Khalil W, Kahm J, Jessurun J, Kleidon J, Henke CA. Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Am J Pathol 2010;176:2626-2637.
18. Xia H, Seeman J, Hong J, Hergert P, Bodem V, Jessurun J, Smith K, Nho R, Kahm J, Gaillard P, et al. Low α2β1 integrin function enhances the proliferation of fibroblasts from patients with idiopathic pulmonary fibrosis by activation of the β-catenin pathway. Am J Pathol 2012;181:222-233.
19. Ivaska J, Nissinen L, Immonen N, Eriksson JE, Kahari VM, Heino J. Integrin α2β1 promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3β. Mol Cell Biol 2002;22:1352-1359.
20. Guo W, Shan B, Klingsberg RC, Qin X, Lasky JA. Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition. Am J Physiol Lung Cell Mol Physiol 2009;297: L864-L870.
21. Paroni G, Cernotta N, Dello Russo C, Gallinari P, Pallaoro M, Foti C, Talamo F, Orsatti L, Steinkuhler C, Brancolini C. PP2A regulates HDAC4 nuclear import. Mol Biol Cell 2008;19:655-667.
22. Miska EA, Karlsson C, Langley E, Nielsen SJ, Pines J, Kouzarides T. HDAC4 deacetylase associates with and represses the MEF2 transcription factor. EMBO J 1999;18:5099-5107.
23. Backs J, Worst BC, Lehmann LH, Patrick DM, Jebessa Z, Kreusser MM, Sun Q, Chen L, Heft C, Katus HA, et al. Selective repression of MEF2 activity by PKA-dependent proteolysis of HDAC4. J Cell Biol 2011;195:403-415.
24. Liu F, Dowling M, Yang XJ, Kao GD. Caspase-mediated specific cleavage of human histone deactylase 4. J Biol Chem 2004;279: 34537-34546.
25. Cohen TJ, Barrientos T, Hartman ZC, Garvey SM, Cox GA, Yao TP. The deacetylase HDAC4 controls myocyte enhancing factor-2-dependent structural gene expression in response to neural activity. FASEB J 2009;23:99-106.
26. Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, Meadows E, McAnally J, Pomajzl C, Shelton JM, Richardson JA, et al. Histone deactylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004;119:555-566.
27. Zhuang Q, Xiaobing Q, Yue Y, Wu H, Benda C, Lin J, Huang Z, Liu L, Xu Y, Bao X, et al. Class IIa histone deacetylases and MEF2 proteins regulate the mesenchymal-to-epithelial transition of somatic cell reprogramming. J Biol Chem 2013;288:12022-12031.
28. Mottet D, Pirotte S, Lamour V, Hagedorn M, Javerzat S, Bikfalvi A, Bellahcene A, Verdin E, Castronovo V. HDAC4 represses p21 (WAF/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene 2009;28:242-256.
29. Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D, Figueroa M, Melnick A, Kao GD, Augenlicht LH, et al. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell 2008;19:4062-4075.
30. Mannaerts I, Eysackers N, Onyema OO, Van Beneden K, Valente S, Mai A, Odenthal M, van Grunsven LA. Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29. PLoS One 2013;8:E55786.
31. Larsson O, Diebold D, Fan D, Peterson M, Nho RS, Bitterman PB, Henke CA. Fibrotic myofibroblasts manifest genome-wide derangements of translational control. PLoS One 2008;3:e3220.
32. Parker MW, Rossi D, Peterson M, Smith K, Sikström K, White ES, Connett JE, Henke CA, Larsson O, Bitterman PB. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest 2014;124:1622-1635.
33. Ramos C, Montano M, Garcia-Alvarez J, Ruiz V, Uhal BD, Selman M, Pardo A. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol 2001;24:591-598.
34. Booth AJ, Hadley R, Cornett AM, Dreffs AA, Matthes SA, Tsui JL, Weiss K, Horowitz JC, Fiore VF, Barker TH, et al. Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med 2012;186:866-876.
35. Olsen KC, Sapinoro RE, Kottman RM, Kulkarni AA, Iismaa SE, Johnson GV, Thatcher TH, Phipps RP, Sime PJ. Transglutaminase 2 and its role in pulmonary fibrosis. Am J Respir Crit Care Med 2011;184: 699-707.
36. Liu F, Mih JD, Shea BS, Kho AT, Sharif AS, Tager AM, Tschumperlin DJ. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biol 2010;190:693-706.
37. Marinkovic A, Liu F, Tschumperlin D. Matrices of physiologic stiffness potently inactivate idiopathic pulmonary fibrosis fibroblasts. Am J Respir Cell Mol Biol 2013;48:422-430.
38. Huang X, Yang N, Fiore VF, Barker TH, Sun Y, Morris SW, Ding Q, Thannickal VJ, Zhou Y. Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction. Am J Respir Cell Mol Biol 2012;47:340-348.
39. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, White JG, Keely PJ. Collagen density promotes mammary tumor initiation and progression. BMC Med 2008;6:11.
40. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009;139: 891-906.
41. Cox TR, Bird D, Baker AM, Barker HE, Ho MWY, Lang G, Erler JT. Lox-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res 2013;73:1721-1732.
42. Ramirez NE, Zhang Z, Madamanchi A, Boyd KL, O'Rear LD, Nashabi A, Li Z, Dupont WD, Zijlstra A, Zutter MM. The α2β1 integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest 2011;121:226-237.
43. Grzesiak JJ, Bouvet M. The α2β1 integrin mediates the malignant phenotype on type I collagen in pancreatic cancer cell lines. Br J Cancer 2006;94:1311-1319.
44. Sottnik JL, Daignault-Newton S, Zhang X, Morrissey C, Hussain MH, Keller ET, Hall CL. Integrin α2β1 promotes prostate cancer skeletal metastasis. Clin Exp Metastasis 2013;30:569-578.
45. Marthick JR, Dickinson JL. Emerging putative biomarkers: the role of alpha 2 and 6 integrins in susceptibility, treatment, and prognosis. Prostate Cancer 2012;2012:298732.
46. Kirkland SC, Ying H. α2β1 integrin regulates lineage commitment in multipotent human colorectal cells. J Biol Chem 2008;283:27612-27619.
47. Balestrini JL, Chaudry S, Sarrazy V, Koehler A, Hinz B. The mechanical memory of lung myofibroblasts. Integr Biol (Camb) 2012;4:410-421.
48. Liu S, Wu L-C, Pang J, Santhanam R, Wu Y-Z, Hickley CJ, Yu J, Becker H, Maharry K, Radmacher MD, et al. SP1/NFkB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 2010;17:333-347.